Candriam S.C.A. boosted its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 1.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,110,424 shares of the company’s stock after buying an additional 18,123 shares during the quarter. Candriam S.C.A.’s holdings in IDEAYA Biosciences were worth $42,818,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Sterling Capital Management LLC increased its holdings in IDEAYA Biosciences by 20.5% during the third quarter. Sterling Capital Management LLC now owns 1,873 shares of the company’s stock valued at $72,000 after buying an additional 319 shares during the last quarter. Covestor Ltd raised its position in IDEAYA Biosciences by 21.1% in the third quarter. Covestor Ltd now owns 3,178 shares of the company’s stock worth $122,000 after acquiring an additional 554 shares during the period. Versant Capital Management Inc raised its position in IDEAYA Biosciences by 26.7% in the second quarter. Versant Capital Management Inc now owns 2,825 shares of the company’s stock worth $105,000 after acquiring an additional 596 shares during the period. Hsbc Holdings PLC boosted its stake in shares of IDEAYA Biosciences by 3.9% during the 1st quarter. Hsbc Holdings PLC now owns 19,258 shares of the company’s stock worth $645,000 after acquiring an additional 725 shares during the last quarter. Finally, ProShare Advisors LLC boosted its stake in shares of IDEAYA Biosciences by 6.3% during the 3rd quarter. ProShare Advisors LLC now owns 14,740 shares of the company’s stock worth $566,000 after acquiring an additional 876 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors.
IDEAYA Biosciences Trading Up 1.9%
IDEAYA Biosciences stock opened at $31.24 on Friday. The firm has a 50 day moving average of $36.28 and a 200 day moving average of $33.98. The firm has a market capitalization of $3.02 billion, a price-to-earnings ratio of -6.96 and a beta of 0.08. IDEAYA Biosciences, Inc. has a 12-month low of $26.81 and a 12-month high of $42.68.
IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.04). IDEAYA Biosciences had a negative return on equity of 39.78% and a negative net margin of 1,157.18%. The firm had revenue of $10.24 million for the quarter, compared to the consensus estimate of $7.58 million. During the same quarter in the previous year, the business posted $1.33 EPS. IDEAYA Biosciences’s revenue was up 14.6% on a year-over-year basis. On average, analysts predict that IDEAYA Biosciences, Inc. will post -4.62 EPS for the current year.
Insider Buying and Selling at IDEAYA Biosciences
In other news, CEO Yujiro Hata sold 26,338 shares of the stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $37.41, for a total value of $985,304.58. Following the completion of the sale, the chief executive officer directly owned 690,695 shares of the company’s stock, valued at $25,838,899.95. This represents a 3.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.70% of the stock is currently owned by insiders.
Analyst Ratings Changes
A number of brokerages have recently issued reports on IDYA. Citigroup boosted their price objective on shares of IDEAYA Biosciences from $65.00 to $66.00 and gave the company a “buy” rating in a research report on Thursday. Jefferies Financial Group restated a “buy” rating on shares of IDEAYA Biosciences in a research note on Tuesday, September 1st. Citizens Jmp reaffirmed a “market outperform” rating and issued a $42.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, September 1st. Stifel Nicolaus started coverage on IDEAYA Biosciences in a research report on Wednesday, October 14th. They set a “buy” rating and a $48.00 target price on the stock. Finally, William Blair assumed coverage on IDEAYA Biosciences in a report on Friday, October 16th. They set an “outperform” rating for the company. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, IDEAYA Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.
View Our Latest Research Report on IDEAYA Biosciences
IDEAYA Biosciences Profile
IDEAYA Biosciences, Inc (NASDAQ:IDYA) is a biotechnology company focused on discovering and developing precision medicines for cancer. Its research emphasizes synthetic lethality, biomarker-driven drug discovery and molecularly defined patient populations, with the goal of matching targeted therapies to specific genetic alterations in tumors.
The company’s pipeline includes darovasertib, an investigational protein kinase C inhibitor being studied primarily for genetically defined cancers, including metastatic uveal melanoma.
Featured Articles
- Five stocks we like better than IDEAYA Biosciences
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Want to see what other hedge funds are holding IDYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report).
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
